Close Menu

NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2018 Q1 net loss shrank 19 percent year over year, as it moves forward with studies intended to support a final clinical validation by the end of the year.

The liquid biopsy firm's net loss for the three months ended March 31, 2018 was $3.8 million, or $.12 per share, compared to a net loss of $4.7 million, or $.16 per share, in the same quarter last year. It matched the consensus Wall Street estimate of a loss of $.12 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.